Table 4:
Univariable analysis for predictors of CSR after thymectomy
| Variables | Total (n = 134) | CSR (n = 41) | HR (95% CI) | P-value |
|---|---|---|---|---|
| Sex | ||||
| Male | 65 | 20 (30.8%) | 1.075 (0.581–1.673) | 0.839 |
| Female | 69 | 21 (30.4%) | 1 | |
| Onset age | ||||
| <40 years | 75 | 26 (34.7%) | 2.073 (1.084–3.965) | 0.048* |
| ≥40 years | 59 | 15 (25.4%) | 1 | |
| Symptom duration | ||||
| <1 year | 81 | 30 (37.0%) | 4.106 (1.628–9.750) | 0.005* |
| ≥1 year | 53 | 11 (20.2%) | 1 | |
| MGFA clinical classification | ||||
| I | 63 | 24 (38.1%) | 3.154 (1.260–6.729) | 0.029* |
| II and above | 71 | 17 (24.0%) | 1 | |
| Pathology | ||||
| Non-thymoma | 93 | 30 (32.3%) | 1.472 (0.906–3.281) | 0.382 |
| Thymoma | 41 | 11 (26.7%) | 1 | |
| Surgical approach | ||||
| STT | 64 | 20 (31.3%) | 1.193 (0.703–2.065) | 0.947 |
| UTT | 70 | 21 (30.0%) | 1 |
CI: confidence interval; CSR: complete stable remission; HR: hazard ratio; MGFA: Myasthenia Gravis Foundation of America; STT: subxiphoid-subcostal thoracoscopic thymectomy; UTT: uilateral thoracoscopic thymectomy.